Vapotherm Reports Third Quarter 2022 Financial Results
Vapotherm (NYSE: VAPO) reported third quarter 2022 revenues of $13.5 million, down 64.5% year-over-year, impacted by lower demand compared to the prior year's COVID surge. U.S. disposable revenue saw a modest 19.6% increase from the previous quarter, reaching $9.5 million. The company expects 2022 revenues to range between $64 million and $66 million, reflecting a light flu season. Operating expenses decreased significantly to between $94 million and $96 million, while gross margin is projected between 22% and 24%. Net loss for Q3 2022 was $26.2 million, or $0.98 per share.
- Sequential revenue increase of 4.4% from Q2 2022.
- Significant reduction in cash operating expenses from $100 million in 2021 to an estimated $60 million to $62 million in 2023.
- Improvement in disposables turn rates reaching 60% of the three-year pre-COVID average.
- Total revenue down 64.5% year-over-year due to lower demand post-COVID surge.
- Net loss increased to $26.2 million in Q3 2022, compared to $13.6 million in Q3 2021.
- Lower gross margin of 13.8%, affected by inventory reserves and write-offs.
Third Quarter 2022 Summary
-
Total revenue for the third quarter of 2022 was
, an increase of$13.5 million 4.4% over the second quarter of 2022 -
U.S. disposables revenue of reflects a$9.5 million 19.6% increase overU.S. disposables revenue of in the second quarter of 2022$7.9 million -
Cost structure has been streamlined which will result in a decrease in Non-GAAP cash operating expenses from
in 2021 to$100 million to$60 million in 2023$62 million -
Move of manufacturing operations from
New Hampshire toMexico is on track
“Our revenue increased sequentially from the second quarter to the third quarter which is not typical given the seasonality in our business,” said Joseph Army, President and CEO. “Growth was driven primarily by consistent monthly improvement in
Results for the Three Months
The following table reflects the Company’s net revenue for the three months ended
|
|
Three Months Ended |
|
|
|
|
|
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||||||||||
|
|
(in thousands, except percentages) |
|
|||||||||||||||||||||
|
|
Amount |
|
|
% of Revenue |
|
|
Amount |
|
|
% of Revenue |
|
|
$ |
|
|
% |
|
||||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Capital (product & lease revenue) |
|
$ |
1,993 |
|
|
|
14.7 |
% |
|
$ |
15,113 |
|
|
|
39.7 |
% |
|
$ |
(13,120 |
) |
|
|
(86.8 |
)% |
Disposables |
|
|
9,463 |
|
|
|
69.9 |
% |
|
|
21,674 |
|
|
|
56.9 |
% |
|
|
(12,211 |
) |
|
|
(56.3 |
)% |
Service and other |
|
|
2,089 |
|
|
|
15.4 |
% |
|
|
1,328 |
|
|
|
3.4 |
% |
|
|
761 |
|
|
|
57.3 |
% |
Total net revenue |
|
$ |
13,545 |
|
|
|
100.0 |
% |
|
$ |
38,115 |
|
|
|
100.0 |
% |
|
$ |
(24,570 |
) |
|
|
(64.5 |
)% |
Net revenue for the third quarter of 2022 was
Revenue information by geography is summarized as follows:
|
|
Three Months Ended |
|
|
|
|
|
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||||||||||
|
|
(in thousands, except percentages) |
|
|||||||||||||||||||||
|
|
Amount |
|
|
% of Revenue |
|
|
Amount |
|
|
% of Revenue |
|
|
$ |
|
|
% |
|
||||||
|
|
$ |
11,063 |
|
|
|
81.7 |
% |
|
$ |
32,950 |
|
|
|
86.4 |
% |
|
$ |
(21,887 |
) |
|
|
(66.4 |
)% |
International |
|
|
2,482 |
|
|
|
18.3 |
% |
|
|
5,165 |
|
|
|
13.6 |
% |
|
|
(2,683 |
) |
|
|
(51.9 |
)% |
Total net revenue |
|
$ |
13,545 |
|
|
|
100.0 |
% |
|
$ |
38,115 |
|
|
|
100.0 |
% |
|
$ |
(24,570 |
) |
|
|
(64.5 |
)% |
Gross profit and gross margin for the third quarter of 2022 was
Total operating expenses were
Net loss for the third quarter of 2022 was
Adjusted EBITDA was negative
Cash Position
Cash and cash equivalents were
Fiscal 2022 Outlook
For fiscal 2022, the Company expects net revenue to be in the range of
For fiscal 2022, gross margin is expected to be in the range of
For fiscal 2022, operating expenses excluding impairment charges are expected to be in the range of
For fiscal 2022, operating expenses excluding impairment charges, depreciation and amortization, stock-based compensation expense, change in the value of contingent consideration and the impact of severance accruals are expected to be in the range of
The Company is evaluating various capital raising options while it continues to execute on its path-to-profitability initiative which includes converting
Conference Call
Management will host a conference call at
Website Information
Non-GAAP Financial Measures
This press release includes non-GAAP financial measures, including EBITDA, Adjusted EBITDA, operating expenses excluding impairment charges, loss on disposal of property and equipment, depreciation and amortization, stock-based compensation expense, change in the value of contingent consideration and the impact of severance accruals recorded, which non-GAAP measures differ from financial measures calculated in accordance with
These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses Adjusted EBITDA and non-GAAP operating expenses, excluding certain items, as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period.
These non-GAAP financial measures should not be considered alternatives to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our capital expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using Adjusted EBITDA and other non-GAAP financial measures on a supplemental basis. The Company’s definition of Adjusted EBITDA is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
About
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company’s expected net revenue, gross margin and operating expenses for fiscal year 2022, its expectations to execute on its path-to-profitability initiative, raise additional capital, convert
Financial Statements:
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) |
||||||||
|
|
|
|
|
|
|
||
|
|
(unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
28,709 |
|
|
$ |
57,071 |
|
Accounts receivable, net |
|
|
8,136 |
|
|
|
10,909 |
|
Inventories, net |
|
|
36,433 |
|
|
|
36,562 |
|
Prepaid expenses and other current assets |
|
|
3,201 |
|
|
|
5,205 |
|
Total current assets |
|
|
76,479 |
|
|
|
109,747 |
|
Property and equipment, net |
|
|
25,694 |
|
|
|
22,157 |
|
Operating lease right-of-use assets |
|
|
6,676 |
|
|
|
7,045 |
|
Restricted cash |
|
|
1,109 |
|
|
|
253 |
|
|
|
|
494 |
|
|
|
15,300 |
|
Intangible assets, net |
|
|
25 |
|
|
|
4,398 |
|
Deferred income tax assets |
|
|
32 |
|
|
|
78 |
|
Other long-term assets |
|
|
2,115 |
|
|
|
1,107 |
|
Total assets |
|
$ |
112,624 |
|
|
$ |
160,085 |
|
Liabilities and Stockholders’ (Deficit) Equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,507 |
|
|
$ |
5,923 |
|
Contract liabilities |
|
|
1,478 |
|
|
|
2,081 |
|
Accrued expenses and other current liabilities |
|
|
16,707 |
|
|
|
28,559 |
|
Revolving loan facility |
|
|
- |
|
|
|
6,608 |
|
Total current liabilities |
|
|
19,692 |
|
|
|
43,171 |
|
Long-term loans payable, net |
|
|
96,815 |
|
|
|
39,726 |
|
Other long-term liabilities |
|
|
7,018 |
|
|
|
10,521 |
|
Total liabilities |
|
|
123,525 |
|
|
|
93,418 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ (deficit) equity |
|
|
|
|
|
|
||
Preferred stock ( |
|
|
- |
|
|
|
- |
|
Common stock ( |
|
|
27 |
|
|
|
26 |
|
Additional paid-in capital |
|
|
458,023 |
|
|
|
443,358 |
|
Accumulated other comprehensive (loss) income |
|
|
(386 |
) |
|
|
26 |
|
Accumulated deficit |
|
|
(468,565 |
) |
|
|
(376,743 |
) |
Total stockholders’ (deficit) equity |
|
|
(10,901 |
) |
|
|
66,667 |
|
Total liabilities and stockholders’ (deficit) equity |
|
$ |
112,624 |
|
|
$ |
160,085 |
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) |
||||||||||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
|
|
(unaudited) |
|
|
(unaudited) |
|
||||||||||
Net revenue |
|
$ |
13,545 |
|
|
$ |
38,115 |
|
|
$ |
48,138 |
|
|
$ |
91,048 |
|
Cost of revenue |
|
|
11,682 |
|
|
|
19,291 |
|
|
|
36,018 |
|
|
|
45,649 |
|
Gross profit |
|
|
1,863 |
|
|
|
18,824 |
|
|
|
12,120 |
|
|
|
45,399 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
4,382 |
|
|
|
3,979 |
|
|
|
16,241 |
|
|
|
13,466 |
|
Sales and marketing |
|
|
11,460 |
|
|
|
20,465 |
|
|
|
36,615 |
|
|
|
47,169 |
|
General and administrative |
|
|
6,477 |
|
|
|
7,262 |
|
|
|
20,754 |
|
|
|
23,948 |
|
Impairment of goodwill |
|
|
- |
|
|
|
- |
|
|
|
14,701 |
|
|
|
- |
|
Impairment of long-lived and intangible assets |
|
|
2,139 |
|
|
|
- |
|
|
|
6,175 |
|
|
|
- |
|
Loss on disposal of property and equipment |
|
|
321 |
|
|
|
- |
|
|
|
321 |
|
|
|
- |
|
Total operating expenses |
|
|
24,779 |
|
|
|
31,706 |
|
|
|
94,807 |
|
|
|
84,583 |
|
Loss from operations |
|
|
(22,916 |
) |
|
|
(12,882 |
) |
|
|
(82,687 |
) |
|
|
(39,184 |
) |
Other (expense) income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest expense |
|
|
(3,276 |
) |
|
|
(647 |
) |
|
|
(7,872 |
) |
|
|
(1,960 |
) |
Interest income |
|
|
56 |
|
|
|
21 |
|
|
|
113 |
|
|
|
74 |
|
Foreign currency loss |
|
|
(73 |
) |
|
|
(58 |
) |
|
|
(188 |
) |
|
|
(188 |
) |
Loss on extinguishment of debt |
|
|
- |
|
|
|
- |
|
|
|
(1,114 |
) |
|
|
- |
|
Other |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
18 |
|
Net loss before income taxes |
|
$ |
(26,209 |
) |
|
$ |
(13,566 |
) |
|
$ |
(91,748 |
) |
|
$ |
(41,240 |
) |
(Benefit) provision for income taxes |
|
|
(8 |
) |
|
|
- |
|
|
|
74 |
|
|
|
- |
|
Net loss |
|
$ |
(26,201 |
) |
|
$ |
(13,566 |
) |
|
$ |
(91,822 |
) |
|
$ |
(41,240 |
) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign currency translation adjustments |
|
|
(172 |
) |
|
|
(40 |
) |
|
|
(412 |
) |
|
|
(22 |
) |
Total other comprehensive loss |
|
|
(172 |
) |
|
|
(40 |
) |
|
|
(412 |
) |
|
|
(22 |
) |
Total comprehensive loss |
|
$ |
(26,373 |
) |
|
$ |
(13,606 |
) |
|
$ |
(92,234 |
) |
|
$ |
(41,262 |
) |
Net loss per share basic and diluted |
|
$ |
(0.98 |
) |
|
$ |
(0.52 |
) |
|
$ |
(3.46 |
) |
|
$ |
(1.59 |
) |
Weighted-average number of shares used in calculating net
|
|
|
26,697,226 |
|
|
|
25,987,648 |
|
|
|
26,532,159 |
|
|
|
25,891,045 |
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) |
||||||||
|
|
|
|
|
|
|
||
|
|
Nine Months Ended |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
(91,822 |
) |
|
$ |
(41,240 |
) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
|
||
Stock-based compensation expense |
|
|
7,625 |
|
|
|
7,197 |
|
Depreciation and amortization |
|
|
4,006 |
|
|
|
4,181 |
|
Provision for bad debts |
|
|
346 |
|
|
|
(110 |
) |
Provision for inventory valuation |
|
|
2,655 |
|
|
|
- |
|
Non-cash lease expense |
|
|
1,670 |
|
|
|
1,304 |
|
Change in fair value of contingent consideration |
|
|
(3,351 |
) |
|
|
(457 |
) |
Impairment of goodwill |
|
|
14,701 |
|
|
|
- |
|
Impairment of long-lived and intangible assets |
|
|
6,175 |
|
|
|
- |
|
Loss on disposal of property and equipment |
|
|
546 |
|
|
|
126 |
|
Amortization of discount on debt |
|
|
502 |
|
|
|
55 |
|
Deferred income taxes |
|
|
74 |
|
|
|
12 |
|
Loss on extinguishment of debt |
|
|
1,114 |
|
|
|
- |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
2,338 |
|
|
|
2,776 |
|
Inventories |
|
|
(2,651 |
) |
|
|
(4,861 |
) |
Prepaid expenses and other assets |
|
|
(1,902 |
) |
|
|
(1,102 |
) |
Accounts payable |
|
|
(4,295 |
) |
|
|
(854 |
) |
Contract liabilities |
|
|
(562 |
) |
|
|
(658 |
) |
Accrued expenses and other current liabilities |
|
|
(4,853 |
) |
|
|
(4,286 |
) |
Operating lease liabilities, current and long-term |
|
|
(1,581 |
) |
|
|
(1,305 |
) |
Net cash used in operating activities |
|
|
(69,265 |
) |
|
|
(39,222 |
) |
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
(8,266 |
) |
|
|
(4,814 |
) |
Net cash used in investing activities |
|
|
(8,266 |
) |
|
|
(4,814 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
||
Proceeds from loans, net of discount |
|
|
99,094 |
|
|
|
- |
|
Repayment of loans |
|
|
(40,000 |
) |
|
|
- |
|
Payments of debt extinguishment costs |
|
|
(817 |
) |
|
|
- |
|
Payment of debt issuance costs |
|
|
(1,567 |
) |
|
|
- |
|
Repayments on revolving loan facility |
|
|
(6,608 |
) |
|
|
(3,163 |
) |
Payment of contingent consideration |
|
|
(135 |
) |
|
|
- |
|
Proceeds from exercise of stock options |
|
|
65 |
|
|
|
1,405 |
|
Proceeds from issuance of common stock under Employee Stock Purchase Plan |
|
|
135 |
|
|
|
851 |
|
Net cash provided by (used in) financing activities |
|
|
50,167 |
|
|
|
(907 |
) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
(142 |
) |
|
|
(5 |
) |
Net decrease in cash, cash equivalents and restricted cash |
|
|
(27,506 |
) |
|
|
(44,948 |
) |
Cash, cash equivalents and restricted cash |
|
|
|
|
|
|
||
Beginning of period |
|
|
57,324 |
|
|
|
115,536 |
|
End of period |
|
$ |
29,818 |
|
|
$ |
70,588 |
|
Supplemental disclosures of cash flow information |
|
|
|
|
|
|
||
Interest paid during the period |
|
$ |
6,023 |
|
|
$ |
1,862 |
|
Property and equipment purchases in accounts payable and accrued expenses |
|
$ |
617 |
|
|
$ |
133 |
|
Issuance of common stock to satisfy contingent consideration |
|
$ |
5,630 |
|
|
$ |
- |
|
Issuance of common stock warrants in conjunction with long term debt |
|
$ |
1,196 |
|
|
$ |
- |
|
Issuance of common stock upon vesting of restricted stock units |
|
$ |
15 |
|
|
$ |
133 |
|
Non-GAAP Financial Measures
The following tables contain a reconciliation of net loss to Adjusted EBITDA for the three months ended
(unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
|
|
(in thousands) |
|
|||||
Net loss |
|
$ |
(26,201 |
) |
|
$ |
(13,566 |
) |
Interest expense, net |
|
|
3,220 |
|
|
|
626 |
|
Benefit for income taxes |
|
|
(8 |
) |
|
|
- |
|
Depreciation and amortization |
|
|
1,267 |
|
|
|
1,318 |
|
EBITDA |
|
$ |
(21,722 |
) |
|
$ |
(11,622 |
) |
Foreign currency |
|
|
73 |
|
|
|
58 |
|
Change in fair value of contingent consideration |
|
|
(238 |
) |
|
|
(1,220 |
) |
Stock-based compensation |
|
|
1,681 |
|
|
|
2,079 |
|
Impairment of long-lived and intangible assets |
|
|
2,139 |
|
|
|
- |
|
Loss on disposal of property and equipment |
|
|
321 |
|
|
|
- |
|
Adjusted EBITDA |
|
$ |
(17,746 |
) |
|
$ |
(10,705 |
) |
The following tables contain a reconciliation of operating expenses to cash operating expenses for the three months ended
(unaudited)
|
|
Three Months Ended |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||
|
|
(in thousands) |
|
|||||||||
GAAP operating expenses |
|
$ |
24,779 |
|
|
$ |
42,203 |
|
|
$ |
31,706 |
|
Impairment of goodwill |
|
|
- |
|
|
|
(14,701 |
) |
|
|
- |
|
Impairment of long-lived and intangible assets |
|
|
(2,139 |
) |
|
|
(4,036 |
) |
|
|
- |
|
Loss on disposal of property and equipment |
|
|
(321 |
) |
|
|
- |
|
|
|
- |
|
Stock-based compensation |
|
|
(1,488 |
) |
|
|
(2,304 |
) |
|
|
(1,898 |
) |
Termination benefits |
|
|
(1,186 |
) |
|
|
(1,844 |
) |
|
|
- |
|
Depreciation and amortization |
|
|
(395 |
) |
|
|
(500 |
) |
|
|
(467 |
) |
Change in fair value of contingent consideration |
|
|
238 |
|
|
|
2,925 |
|
|
|
1,220 |
|
Non-GAAP cash operating expenses |
|
$ |
19,488 |
|
|
$ |
21,743 |
|
|
$ |
30,561 |
|
Supplemental Operating Metrics
|
|
|
|
|
|
|
|
|
|||||||
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||
|
Amount |
|
|
Amount |
|
|
Amount |
|
|
% |
|
||||
HVT 2.0 and precision flow units installed base |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
23,998 |
|
|
|
22,911 |
|
|
|
1,087 |
|
|
|
4.7 |
% |
International |
|
12,328 |
|
|
|
11,623 |
|
|
|
705 |
|
|
|
6.1 |
% |
Total |
|
36,326 |
|
|
|
34,534 |
|
|
|
1,792 |
|
|
|
5.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Three Months Ended |
|
|
|
|
|
|
|
|||||||
|
2022 |
|
|
2021 |
|
|
Change |
|
|||||||
|
Amount |
|
|
Amount |
|
|
Amount |
|
|
% |
|
||||
HVT 2.0 and precision flow units sold and leased |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
123 |
|
|
|
1,891 |
|
|
|
(1,768 |
) |
|
|
(93.5 |
)% |
International |
|
51 |
|
|
|
556 |
|
|
|
(505 |
) |
|
|
(90.8 |
)% |
Total |
|
174 |
|
|
|
2,447 |
|
|
|
(2,273 |
) |
|
|
(92.9 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Disposable patient circuits sold |
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
71,818 |
|
|
|
168,471 |
|
|
|
(96,653 |
) |
|
|
(57.4 |
)% |
International |
|
20,854 |
|
|
|
31,501 |
|
|
|
(10,647 |
) |
|
|
(33.8 |
)% |
Total |
|
92,672 |
|
|
|
199,972 |
|
|
|
(107,300 |
) |
|
|
(53.7 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005652/en/
Investor Relations Contacts:
Source:
FAQ
What were Vapotherm's third quarter 2022 earnings results?
What is Vapotherm's revenue outlook for fiscal 2022?
How did Vapotherm's operating expenses change in Q3 2022?